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1. Introduction 
Diagnostic nuclear medicine (NM) is among the imaging procedures (together with X-ray, 
computerized tomography, magnetic resonance, and echography) the clinicians can routinely 
adopt to image organs or tissues and related disorders. In this chapter, we will describe the 
role of nuclear medicine imaging in diagnosis of the brain tumors, application of metal 
complex-carbohydrates for this purpose and review how these imaging approaches can 
contribute to the diagnosis of disease. The chapter is organized into the following sections: 
1. Background  
2. Current state of nuclear medicine imaging for brain tumor imaging   
3. Introduction another new compounds for brain tumor imaging 
2. Background 
2.1 Brain tumor 
The brain tumor experience can be a journey into an unknown land filled with uncertainty. 
Brain tumors occurs when brain cells become abnormal and form cells in an uncontrolled 
manner. These extra brain cells form into a mass of tissue, also known as a tumor, which can 
be a classified as benign brain tumor, a mass of extra cells that are harmless and have 
distinct boundaries, or malignant, a mass of extra cells that are life-threatening and either 
cancerous or located in a vital brain area. For the most part, malignant brain tumors are 
indicative of cancer and the American Cancer Society estimate that malignant brain tumors 
will result in approximately 13,100 deaths (1.4% of all cancer deaths) in 2004. Although there 
are a number of different methods to classify brain tumors, the best way to distinguish 
between brain tumors is by classifying them as primary brain tumors and  secondary brain 
tumors. A brain tumor diagnosis usually involves several steps, which can include a 
neurological examination, brain scan(s) and/or a biopsy and nuclear medicine imaging. 
2.2 Brain tumor diagnosis methods 
Identifying a brain tumor usually involves a neurological examination, brain scans, and/or 
an analysis of the brain tissue. Doctors use the diagnostic information to classify the tumor 
from the least aggressive (benign) to the most aggressive (malignant). In most cases, a brain 
tumor is named for the cell type of origin or its location in the brain. Identifying the type of 
tumor helps doctors determine the most appropriate course of treatment. 
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A neurological examination is a series of tests to measure the function of the patient nervous 
system and physical and mental alertness. If responses to the exam are not normal, the 
doctor may order a brain scan or refer the patient to a neurologist or neurosurgeon, who 
will then order a brain scan. 
 A brain scan is a picture of the internal structures in the brain. A specialized machine takes a 
scan in much the same way a digital camera takes a photograph. Using computer 
technology, a scan compiles an image of the brain by photographing it from various angles. 
Some types of scans use a contrast agent (or contrast dye), which helps the doctor see the 
difference between normal and abnormal brain tissue. The contrast agent is injected into a 
vein and flows into brain tissue. Abnormal or diseased brain tissue absorbs more dye than 
normal healthy tissue. The most common scans used for diagnosis are as follows: 
a. MRI (Magnetic Resonance Imaging) is a scanning device that uses magnetic fields and 
computers to capture images of the brain on film.  
b. CT or CAT Scan (Computed Tomography) combines sophisticated x-ray and computer 
technology. CT can show a combination of soft tissue, bone, and blood vessels. CT 
images can determine some types of tumors, as well as help detect swelling, bleeding, 
and bone and tissue calcification. Usually, iodine is the contrast agent used during a CT 
scan. 
c. Nuclear Medicine Imaging provides a picture of the brains activity, rather than its 
structure. Nuclear medicine imaging non-invasively provides functional information at 
the molecular and cellular level that contributes to the determination of health status by 
measuring the uptake and turnover of target-specific radiotracers in tissue. These 
functional processes include tissue blood flow and metabolism, protein—protein 
interactions, expression of cell receptors in normal and abnormal cells, cell—cell 
interactions, neurotransmitter activity, cell trafficking and homing, tissue invasion, and 
programmed cell death. By providing information on these processes, nuclear medicine 
imaging offers a broad array of tools for probing normal and disease-related states of 
tissue function and response to treatment.  The addition of anatomic imaging provided 
by computed tomography (CT) to functional imaging of positron emission tomography 
(PET) and single photon emission computed tomography (SPECT) has further 
expanded the utility and accuracy of nuclear medicine imaging (Committee on State of 
the Science of Nuclear Medicine, 2007). 
d. Molecular imaging is expected to have a major impact on the treatment and management 
of brain tumors. 
2.3 Diagnostic nuclear medicine and imaging techniques 
Nuclear medicine is a highly multi-disciplinary specialty that develops and uses 
instrumentation and radiopharmaceuticals to study physiological processes and non-
invasively diagnose, stage, and treat diseases. A radiopharmaceutical is either a 
radionuclide alone, such as iodine-131 (table1) or a radionuclide that is attached to a carrier 
molecule (a drug, protein, or peptide) or particle, which when introduced into the body by 
injection, swallowing, or inhalation accumulates in the organ or tissue of interest. In a 
nuclear medicine scan, a radiopharmaceutical is administered to the patient, and an imaging 
instrument that detects radiation is used to show biochemical changes in the body. Nuclear 
medicine imaging, in contrast to imaging techniques that mainly show anatomy (e.g., 
conventional ultrasound, computed tomography [CT], or magnetic resonance imaging 
[MRI]), can provide important quantitative functional information about normal tissues or 
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disease conditions in living subjects. For treatment, highly targeted radiopharmaceuticals 
may be used to deposit lethal radiation at tumor sites (Committee on State of the Science of 
Nuclear Medicine, 2007). 
 
Application Radionuclide Half-Life Type of Radiation 
Emitted 
Imaging 
Technique Used 
Imaging Carbon-11 20.33 min Positron PET 
″ Nitrogen-13 9.97 min ″ ″ 
″ Oxygen-15 2.04 min ″ ″ 
″ Fluorine-18 109.75 min ″ ″ 
″ Technetium-99m 6.02 hours gamma SPECT 
″ Indium-111 2.8 days ″ ″ 
″ Iodine-123 13 hours ″ ″ 
″ Thallium-201 73 hours ″ ″ 
Therapy Iodine-131 8 days beta  
″ Yttrium-90 2.7 days ″  
Table 1. Commonly used radionuclides for imaging and therapy 
Diagnostic nuclear medicine (DNM) is among the imaging procedures (together with X-ray, 
computerized tomography, magnetic resonance, and echography) the clinicians can 
routinely adopt to image organs or tissues and related disorders. In spite of many advances 
in diagnosis and therapy, brain tumors still represent a serious challenge for clinicians. 
Today, contrast-enhanced CT or MRI is the first examination performed in a patient with 
symptoms typical of brain tumor (i.e. nausea, headache, seizure or focal neurological signs). 
Both MRI and CT allow exactly localizing brain neoplasia and defining the extension of the 
tumoral mass to the surrounding normal tissue. Nevertheless, these techniques present 
some limitations, especially regarding patients’ follow-up after treatments when 
discrimination between tumor recurrence-persistence versus scar tissue is required. In such 
cases, nuclear functional imaging by PET (Positron Emission Tomography) and SPECT 
(Single Photon Emission Computed Tomography) was successfully proposed to obtain a 
metabolic characterization of the morphological lesions detected by MRI or CT scan. By 
using combined-modality PET/CT and SPECT/CT devices, functional processes can be 
localized within the body to an anatomically identified or, in some instances, as yet 
unidentifiable structural alteration. These devices have enhanced the accuracy with which 
disease can be detected, aided in the determination of the extent and severity of disease, 
enhanced the accuracy for identifying disease-related risk, and improved the ability to 
monitor patient response to therapy (Committee on State of the Science of Nuclear 
Medicine, 2007). In diagnostic nuclear medicine two techniques are used for imaging of 
tumors: 
a. PET (Positron Emission Tomography) 
One of the most important uses of Positron Emission Tomography (PET) technology is its 
use in diagnosing and treating brain tumors by measuring the rate at which a tumor absorbs 
glucose derivatives or amino acids. In cases where structural change has been detected 
through MRI or CT, a physician often uses PET imaging to determine the nature of the 
detected structural changes. The PET scan measures the brains activity and sends this 
information to a computer, which creates a live image. Doctors use PET scans to see the 
difference between scar tissue, recurring tumor cells, and necrosis (cells destroyed by 
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radiation treatment). PET imaging is a non-invasive diagnostic imaging tool that has an 
advantage over anatomical imaging tools in that it is a metabolic imaging tool that is able to 
distinguish between benign and malignant tumors. It is often used to accurately determine 
the stage of the brain tumor. Brain tumor PET imaging involves the administration of a 
radioactive tracer that is a combination of a radioisotope (a radioactive compound such as 
18F or 11C whose movements are detectable by a PET scanner) with a natural body 
compound. When used in brain tumor scanning, the radioactive tracer used in PET is 
Fluorodeoxyglucose (FDG), which combines the natural body compound glucose with the 
radioisotope Fluorine-18. This radioactive tracer, or radiopharmaceutical, is used in brain 
PET imaging as the radioactive compound that it uses has a short half-life that will 
disappear from the body within hours. 
The routinely used PET radiotracer 18F-fluorodeoxyglucose (FDG) proved useful to diagnose 
primary brain tumors and their recurrences; moreover, the entity of FDG uptake was found 
to correlate with brain tumor histology. Nevertheless, FDG is physiologically taken by 
normal brain tissue, so this radiotracer is less accurate in detecting very low grade gliomas 
due to their relatively low target to background uptake ratio. To overcome the drawbacks of 
FDG, 11C-methionine was applied in brain tumors imaging. Its uptake is related to the 
increased amino acid transport and protein synthesis and it is accumulated in the neoplastic 
lesion and not in the normal parenchyma. Actually, 11C-methionine proved useful to 
visualize low grade gliomas not detected by FDG (Filippi et al., 2005).  
PET and Brain Tumor Follow-Up 
Besides brain tumor staging, Positron Emission Tomography is a valuable tool in brain 
tumor treatment when it is used as a follow-up to brain tumor treatment. Brain tumors are a 
difficult to fully treat due to the sensitivity of its location. Therefore, brain tumor recurrence 
is often possible. Imaging tests such as magnetic resonance imaging (MRI) and computed 
tomography (CT) are able to be used to detail structural changes, such as tumor formation, 
in the brain. However, these imaging tests often detect structural changes caused by side 
effects from previous brain tumor treatments, such as surgery or radiation therapy. 
b. SPECT (Single Photon Emission Computed Tomography)  
Although PET technology is becoming more and more available in many institutions, its 
diffusion is still limited and it presents very high cost. Moreover, in the case of 11C-
methionine an in situ cyclotron should be available due to the short 11C physical half-life. 
Because the production of 18F requires a cyclotron and the isotope has a short (110 min) half-
life, its utility is somewhat limited compared to that of single photon emission computed 
tomography (SPECT) in nuclear medicine. Although conventional scintigraphy (i.e. single 
photon emission tomography [SPECT] and planar images) presents lower spatial resolution 
when compared to PET, the high diffusion of Anger camera, the device used to perform 
conventional scintigraphy, has accounted for the search of γ-emitting radiotracers as brain 
tumors imaging agents. In terms of developing novel drugs for use in diagnostic and 
therapeutic brain tumor in nuclear medicine, it would be of great interest to label sugars 
(such as glucose and analogue derivatives) and amino acids with the transition metal 
isotopes (such as 99mTc, 186/188Re, 201Tl, 123I, etc.) to substitute the expensive but readily used 
18F-labeled 2-deoxyglucose (18F-FDG) for localization of tumor and metastatic tissue. 
201Tallium was firstly used to detect cerebral neoplasia showing high sensitivity but 
relatively low specificity mainly due to its physical characteristics suboptimal for imaging 
with Anger camera (Filippi et al., 2005). 
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3. Current state of diagnostic nuclear medicine for brain tumor imaging 
3.1 Anatomic imaging procedures (CT scan and MRI) 
 Anatomic imaging procedures (computed tomography [CT] and magnetic resonance 
imaging [MRI]) have become essential tools for brain tumor assessment. Serial MRI is 
routinely performed in these patients after primary treatment to detect tumor recurrence. 
However, conventional contrast-enhanced CT scans or MRI cannot reliably distinguish 
radiation necrosis from recurrent tumor. Both entities can cause extensive edema and 
blood–brain barrier disruption that result in mass effect and abnormal contrast 
enhancement.2,3 Radiation-induced necrosis often occurs within 2 years after radiation 
therapy, the same time frame during which tumor recurrence is most frequent. 
Differentiation between tumor progression and radiation necrosis carries obvious 
prognostic and therapeutic implications. To overcome this problem, several functional and 
physiological imaging techniques, such as MR spectroscopy (MRS), perfusion-weighted 
MRI, positron emission tomography (PET), and thallium-201 single-photon emission 
computed tomography (201Tl-SPECT) have been examined for clinical use (Tie et al., 2008). 
3.2 Functional imaging procedures (PET and SPECT) 
Using anatomical imaging modalities, such as computed tomography (CT) or magnetic 
resonance imaging (MRI), it is difficult to differentiate tumor recurrence from necrosis 
induced by radiotherapy or other treatments. Functional imaging of the brain, in the form 
single photon emission computed tomography (SPECT) utilizing various "tumor seeking" 
tracers, is the most commonly performed investigation to differentiate recurrence from 
necrosis (Barai et al., 2005). Functional imaging procedures (positron emission tomography 
[PET] and singe-photon emission computed tomography [SPECT]) can provide additional 
information useful during the diagnostic workup to determine the degree of malignancy 
and as a substitute or guide for biopsy. After surgery and/or radiotherapy, nuclear 
medicine examinations are essential to assess persistence of tumor, to differentiate 
recurrence from radiation necrosis and gliosis, and to monitor the disease. The combination 
of functional images with anatomic ones is of the utmost importance for a full evaluation of 
these patients, which can be obtained by means of imaging fusion. Brain imaging is 
performed using radiopharmaceuticals by single photon emission computed tomography 
(SPECT) and positron emission tomography (PET). SPECT and PET radiopharmaceuticals 
are classified according to blood-brain-barrier permeability, cerebral perfusion and 
metabolism receptor-binding, and antigen-antibody binding. 
3.2.1 PET radiopharmaceuticals 
PET radiopharmaceuticals for brain imaging are commonly labeled with positron-emitters 
such as 11C, 13N, 15O, and 18F, although other radionuclides such as 82Rb, 62Cu and 68Ga also 
were used. The brain uptake of [13N]glutamate, [68Ga]EDTA and [82Rb]RbCl depends on the 
BBB permeability, but these are rarely used for brain imaging. Several cerebral perfusion 
agents have been introduced, of which [15O]water, [13N]ammonia, and [15O]butanol have 
been used more frequently. Regional CBF has been quantitated by using these tracers in 
normal and different cerebral disease states. Other perfusion agents include [15O]O2, 
[11C]CO, [11C[CO2, [18F]fluoromethane, [15O]O2, [11C]butanol, and [62Cu]PTSM. Among the 
PET cerebral metabolic agents, [18F]fluoro-deoxyglucose (FDG) is most commonly used to 
detect metabolic abnormalities in the brain. Various brain tumors have been graded by 
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[18F]FDG PET. This technique was used to detect epileptic foci by showing increased uptake 
in the foci during the ictal period and decreased uptake in the interictal period. 
Differentiation between recurrent tumors and radiation necrosis and the detection of 
Alzheimer's disease have been made successfully by [18F]FDG PET. Other PET metabolic 
agents such as [11C]deoxyglucose, and [11C]methylmethionine have drawn attention in the 
detection of brain tumors. [18F]fluorodopa is a cerebral neurotransmitter agent, which has 
been found very useful in the detection of Parkinson disease that shows reduced uptake of 
the tracer in the striatum of the brain. The distribution of different receptors in the brain and 
their alteration in different disease states are assessed by using different receptor-binding 
PET radiotracers such as [11C]methylspiperone, [18F]fluoroethylspiperone, 
[18fluoropropylspiperone, [11C]carfentanil, [11C]diprenorphine, [11C]raclopride, 
[11C]flumasenil, and so on (Saha et al., 1994). 
3.2.2 SPECT radiopharmaceuticals 
Despite the fast-growing diffusion of PET, in most cases of brain tumors, SPECT studies are 
adequate and provide results that parallel those obtained with PET. The main limitation of 
SPECT imaging with brain tumor-seeking radiopharmaceuticals is the lack of precise 
anatomic details; this drawback is overcome by the fusion with morphological studies that 
provide an anatomic map to scintigraphic data. In the past, software-based fusion of 
independently performed SPECT and CT or MRI demonstrated usefulness for brain tumor 
assessment, but this process is often time consuming and not practical for everyday nuclear 
medicine studies. The recent development of dual-modality integrated imaging systems, 
which allow the acquisition of SPECT and CT images in the same scanning session, and 
their coregistration by means of the hardware, has facilitated this process. In SPECT studies 
of brain tumors with various radiopharmaceuticals, fused images are helpful in providing 
the precise localization of neoplastic lesions, and in excluding the disease in sites of 
physiologic tracer uptake. This information is useful for optimizing diagnosis, therapy 
monitoring, and radiotherapy treatment planning, with a positive impact on patient 
management. Imaging Fusion of SPECT Studies (Schillaci et al., 2007): 
1. 201Tl 
2. 99mTc Sestamibi  
3. 99mTc Tetrofosmin 
4. 123I-Alpha-Methyl-Tyrosine 
5. 111In-Pentetreotide 
6. Labeled Leukocytes 
a. Clinical used radiopharmaceuticals  
The blood-brain-barrier (BBB) SPECT agents, such as 99mTcO4− [99mTc]DTPA, 201Tl and 
[67Ga]citrate are excluded by normal brain cells, but enter into tumor cells because of altered 
BBB. These agents were used in the earlier period for the detection of brain tumors. SPECT 
perfusion agents such as [123I]IMP, [99mTc]HMPAO, [99mTc]ECD are lipophilic agents and 
therefore, diffuse into the normal brain. These tracers have been successfully used to detect 
various cerebrovascular diseases such as stroke, Parkinson disease, Huntington's disease, 
epilepsy, dementia, and psychiatric disorders. Xenon-133 and radiolabeled microspheres 
have been used for the measurement of cerebral blood flow (CBF). Important receptor-
binding SPECT radiopharmaceuticals include [123I]QNE, [123I]IBZM, and [123I]iomazenil. 
These tracers bind to specific receptors in the brain, thus displaying their distribution in 
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various receptor-related cerebral diseases. Radioiodinated monoclonal antibodies were used 
for the detection of brain tumors. 
A variety of radiolabeled amino acids have been developed as potential tumor imaging 
agents for positron emission tomography (PET) and single photon emission computerized 
tomography (SPECT). Many radiolabeled amino acids developed for tumor imaging enter 
cells via the A-type (sodium dependent) and/or the L-type (sodium independent) transport 
systems, which are upregulated in many neoplasms. The L-type substrate [123I]IMT 
represents the most widely used amino acid for tumor imaging with SPECT (Yu et al., 2008). 
MIBI and Tetrofosmin are technetium labeled compounds which were firstly introduced as 
imaging agent for myocardial scintigraphy. These two radiopharmaceuticals are passively 
accumulated in cells characterized by high metabolic activity so they have been successfully 
used also in oncology (i.e. lung, parathyroid, breast cancer). Regarding brain tumors 
imaging, MIBI was widely applied in diagnosis and follow-up, while few experiences were 
performed using Tetrofosmin. MIBI was proved useful to detect intracranial tumors before 
therapy with higher sensitivity and specificity for gliomas than for the other histologies (i.e. 
lymphomas). Moreover, the entity of MIBI uptake was found to be related to the grade of 
malignancy of gliomas. In patients’ follow-up, MIBI scintigraphy showed great diagnostic 
accuracy to discriminate tumor recurrence versus scar tissue also when compared to CT 
scan. As MIBI is a substrate of Pgp, it was proposed to diagnose chemoresistance in brain 
tumors patients. Nevertheless, the preliminary experiences suggest that Pgp expression is 
inversely related to the grade of malignancy of gliomas so that Pgp seems not to be the main 
cause of chemoresistance in these tumors.  Tetrofosmin scintigraphy presents similar 
characterisitics in sensitivity and specificity as MIBI, so it may represent a suitable tool to 
image brain tumors (Filippi et al., 2005). 
b. New research radiopharmaceuticals 
Flourine-18 (18F) fluorodeoxyglucose (FDG) has been used to measure normal tissue and 
tumor glucose utilization rates. Although metabolic tumor imaging with [18F]-FDG has been 
studied for more than two decades, the use of this examination in clinical practice is still 
limited by factors such as difficult access, limited availability, and high cost. In addition, 
positron emission tomography (PET) radiosynthesis must be performed rapidly because the 
half-life of 18F is only 109 min. Thus, it would be very desirable to develop less costly 
imaging agents based on γ-emitter isotopes, especially for developing countries, where 
single photon emission computed tomography (SPECT) is still dominant. Technetium-99m 
(99mTc) has been mostly used for radiopharmaceuticals labeling due to its suitable physical 
and chemical characteristics and inexpensive isotope cost. Organometallic metal cores often 
exhibit advantages in terms of kinetic inertness, stability, and size and thus could lead to the 
development of more efficient and stable compounds compared to classical inorganic 
complexes. We elected to use the versatile low valent fac-[99mTc(I)-(CO)3] core, which its 
chemistry has recently been pioneered by Alberto and co-workers. The facially coordinated 
carbonyl ligands stabilize the Tc+1 oxidation state, obviating the elaborate, often macrocyclic, 
polydentate structures required to stabilize other intermediate oxidation states of Tc. In 
neutral complexes with simple N,O donors the fac-[99mTc(I)-(CO)3] core possesses 
intermediate lipophilicity, an advantage in living systems. Lots of 99mTc-labeled glucose 
derivatives have been synthesized in order to develop one subrogate in SPECT for [18F]-FDG 
in PET recently. Developed by Yang, 99mTc-labeled ethylenedicysteine-deoxyglucose (EC-
DG) showed similarities with [18F]-FDG in tumor uptake. This suggests that there is 
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feasibility for 99mTc-labeled deoxyglucose as a metabolic tumor imaging agent. However, 
[99mTc]-EC-DG still has some drawbacks such as slow cleanup from the blood, which would 
cause high background activity; and large molecular weight, which would limit its 
penetration through blood–brain barrier (BBB). Thus, it would be desirable to develop a 
smaller 99mTc based deoxyglucose derivative with rapid blood clearance and still 
maintaining its high tumor uptake. In terms of developing novel drugs for use in diagnostic 
nuclear medicine, it would be of great interest to label glucosamine derivatives with 99mTc to 
substitute the expensive but readily used 18F-labeled 2-deoxy glucose (18F-FDG) for 
localization of tumor and metastatic tissue. 99mTc Due to the ideal decay  properties, low cost 
production is used the most frequently in nuclear medicine today. Reported by 
Sadeghzadeh, three glucosamine derivatives showed negligible to moderate brain uptake 
similar to 99mTc-EC (Johari et al., 2007). Compounds (1) and (2) were prepared in one step by 
reaction of glucosamine, ethylcholoroformate and 3-chloro-1,2-propandiol as starting 
materials (Scheme1). 
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Scheme1. Syntesis of two glucosamine derivatives 
The biodistribution of the [99mTc]-1 and  [99mTc]-2 complexes were studied in normal mice 
(body mass 25–35 g) at 30 min and 1 h post-injection, according to a published procedure. 
These complexes showed moderate brain uptake (0.613%±0.03 ID) and (0.512%±0.03 ID) at 
30 min post-injection, an efficient clearance from the blood, a rapid excretion to the urine 
and a low retention in the liver and kidneys. Planar SPECT imaging of the compound1 
showed moderate uptake brain in mice after 2 hours administration (Figure 1).  
At a same work, the proligand 3 is prepared by thioglycolic acid as a starting material 
(Scheme2). The biodistribution of the [99mTc]-(3) complex showed negligible brain uptake 
(0.13%±0.03 ID) at 30 min post-injection (Johari et al., 2007).   
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Fig. 1. Planar SPECT imaging of the compound1 after 2 hours administration. 
 
 
Scheme 2. Synthesis of 2-Amino-2-Deoxy(S-Benzoylthioacetyl)-D-Glucose (3) 
4. New imaging agents for brain tumor diagnosis 
4.1 Molecular imaging (Phosphatidylserine (PS) as a marker for brain tumor)  
Noninvasive molecular-imaging technologies are playing a keyrole in drug discovery, 
development and delivery. Positron Emission Tomography (PET) is such a molecular 
imaging technology and a powerful tool for the observation of various diseases. Anionic 
phospholipids are largely absent from the surface of resting mammalian cells under normal 
conditions. PS, which is the most abundant anionic phospholipid of the plasma membrane, 
is tightly segregated to the internal leaflet of the plasma membrane in most cell types. 
www.intechopen.com
 Diagnostic Techniques and Surgical Management of Brain Tumors 284 
- Anionic phospholipid-targeting agent 
PSVueTM reagents are a family of fluorescent probes containing a bis (Zn2+-dipicolylamine) 
group (Zn-DPA), a motif that has been found to bind with high affinity to surfaces enriched 
with anionic phospholipids, especially phosphatidylserine (PS) exposed on cell membranes 
(Figure 2). The fluorescent part of the probe is a reporter element that provides a means of 
detecting the probe once it is bound to the membrane of interest. Key features of PSVueTM 
Probes are following: (I) Bind to a tumor cells which have negatively charged phospholipids 
exposed on their membranes. (II) Available in a range of detection wavelengths from long-
UV to near infrared. (III) Suitable for  in vitro and in vivo use. (IV) Suitable for high-
throughput screening assays. PSVueTM binds to the same PS site as annexin-V (Qi et al., 
2010). Location of PSVue794 in tumor bearing mice revealed by fluorescence imaging. 
Photon emission from tumors or tissues was detected, digitized and electronically displayed 
as a pseudocolor overlay onto a gray scale animal image. Luminescence and fluorescence 
imaging of excised brains was also performed using the IVIS-200 system (Figure 3). 
 
 
Fig. 2. General structure of PSVueTM Probes 
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Fig. 3. Brian-Tumor Imaging using PSVue794 
Dose-dependent imaging of brain tumor by tail vein injection of  PSVue794 for 24 h (Figure 
4). Left panel: fluorescence imaging with 1 sec imaging time, 745/840 filter set. Right panel 
Luminescnece imaging for tumors with 10 sec imaging time. 
 
 
 
 
 
Fig. 4. Dose-Dependent Brain Tumor Imaging 
4.2 Nanomedicine techniques 
The field of nanomedicine is expected to have a major impact on the treatment and 
management of brain tumors. Over the past decade, significant efforts have been made in 
using nanoparticles for diagnosis and treatment of brain tumors. One class of nanoparticles, 
liposomes, have received considerable attention for use as nanocarriers for delivery of 
therapeutics and contrast agents.  
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